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The Sunscreen Innovation Act was enacted on November
26, 2014, to help expedite the approval process for UV
filters by the US Food and Drug Administration (FDA),
given that no new filters had been approved in several
years. Nearly 5 years later,
on February 26, 2019, the
FDA released a proposed
rule (84 FR 6204)1,2 in response to the Sunscreen Innovation
Act that addressed the classification and labeling of over-
the-counter sunscreen products. A component of this FDA
proposal is to classify the 16 sunscreen active ingredients (ie,
UV filters) listed in the 1999 FDA final monograph into 3 cat-
egories: category I, generally recognized as safe and effective
(GRASE); category II, not GRASE; and category III, insuffi-
cient safety data to support a positive GRASE determination.
Currently, sunscreen manufacturers are working with the
FDA to discuss safety data needed for 8 of the 12 active
ingredients listed in category III.
Another component of the FDA proposal is to require sun-
screen active ingredients to be placed on the principal dis-
play panel of the label to facilitate product comparison.1,2 The
principal display panel is defined by the FDA as the portion of
the label that is most evident when the product is displayed
for retail sale. It should be noted that although changes to sun-
screen labeling have been proposed, little is known regarding
how consumers evaluate and prioritize sunscreen ingredi-
ents in their decision-making and selection of sunscreen prod-
ucts. Therefore, evidence is greatly needed to identify key
points for dermatologists to better educate patients regard-
ing sunscreen as a part of photoprotection.
In this issue of JAMA Dermatology, Tribby and colleagues3
evaluate how the proposed revisions may affect labeling.
The authors explore the usefulness of listing the active ingre-
dients on the principal display panel and the ability of study
participants to recall these ingredients when selecting sun-
screen products. Study participants were shown 2 mock la-
bels, 1 meeting the current FDA guideline and 1 aiming to meet
the proposed FDA guideline. Participants were queried on the
recall of ingredients and how the ingredients influenced their
sunscreen selection. The study found that fewer than 30% of
study participants used information on the active ingredi-
ents as the primary factor in choosing sunscreen and that
only 11% could recall any of the active ingredients after view-
ing both labels.
Only 1 of the 47 participants in the study by Tribby and
colleagues looked at the label to seek environmentally safe
ingredients.3 The main reason for environmental concern is
the association found between the active ingredients in sun-
screen and coral reef bleaching, with oxybenzone being the
most widely discussed UV filter.4,5 In laboratory settings, the
concentration of UV filters required to decrease chlorophyll
content and overall coral cell growth is 1000-fold higher than
that measured in ocean water. Also, it is not clear what rela-
tive contribution sunscreen-derived oxybenzone makes to
marine environments, which may be detrimentally affected
by industrial sources of oxybenzone as well as by global
warming.
On January 1, 2021, Hawaii banned the sale of sunscreen
products containing octinoxate and oxybenzone. On January
21, 2021, the state’s legislature introduced new bills that pro-
pose also banning sunscreens containing avobenzone, homo-
salate, octisalate, and octocrylene.6 However, because of the
relatively small number of FDA-approved UV filters, their re-
moval from the US market is not easily accomplished. There
are limited options for achieving a final sunscreen product with
a high sun protection factor (SPF) and broad-spectrum cover-
age. Approval of other broad-spectrum photostable filters by
the FDA would be most beneficial to achieving this goal. Con-
sidering the varying degrees of environmental awareness and
concerns in different geographic areas, if the study by Tribby
and colleagues3 had been conducted in an area other than
Washington, DC, a higher percentage of participants might
have tried to avoid ingredients with perceived environmen-
tal consequences.
Five of the 47 participants in the study by Tribby and
colleagues3 avoided certain ingredients for personal health rea-
sons. A systematic review of 29 studies7 was recently pub-
lished on the association of octinoxate and oxybenzone with
human health. For oxybenzone, no adverse effects were ob-
served for male or female fertility, female reproductive hor-
mone levels, adiposity, fetal growth, child neurodevelop-
ment, or sexual maturation. While associations with thyroid
hormone, testosterone level, kidney function, and pubertal
timing were reported, causal relationships were not estab-
lished. No reported effect of octinoxate on thyroid or repro-
ductive hormone levels was noted. The authors concluded that
current evidence is not sufficient to support the causal rela-
tionship between an elevated systemic level of octinoxate or
oxybenzone and adverse health outcomes.
In a study by Matta and colleagues,8 scientists at the FDA
showed systemic absorption of 6 organic sunscreen filters when
applied to 75% of the body at a concentration of 2 mg per cm2
(the concentration used in SPF testing). Notably, absorption
was detected even after a single application. This finding was
used to support the need for additional safety testing on sun-
screen filters; however, the authors clearly stated that their re-
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As discussed by Tribby and colleagues,3 a previous study
by Xu and colleagues9 showed that cosmetic elegance is the
most-cited positive feature of highly rated sunscreens. This
study focused on sun-sensitive individuals who typically have
fair skin and may apply products containing inorganic filters
(ie, titanium dioxide and zinc oxide) to maintain a cosmeti-
cally preferred appearance. In consumers with richly pig-
mented skin, sunscreen is used primarily to prevent photoag-
ing and pigmentary problems. This subgroup may favor organic
(also known as chemical) sunscreen filters because inorganic
filters can be cosmetically unacceptable—leaving a white film
on the skin. Further studies are needed on sunscreens and in-
dividuals with richly pigmented skin.
In the US, active ingredients in sunscreens are regulated
by the FDA as over-the-counter drugs. On March 27, 2020,
the Coronavirus Aid, Relief, and Economic Security (CARES)
Act10 was signed into law. Under the CARES Act, the FDA is
to update and finalize requirements for over-the-counter
drugs, including sunscreens, via a streamlined administra-
tive order process intended to improve efficiency, timeli-
ness, and predictability. As a result, a final sunscreen order
will no longer undergo a time-consuming 3-phase process to
be incorporated into the final sunscreen monograph11;
instead, it will automatically be deemed a final administra-
tive order and be effective immediately. Consequently, the
CARES Act will replace the Sunscreen Innovation Act on
September 30, 2022.
Under the CARES Act,10 the FDA is required to issue a pro-
posed administrative order by September 27, 2021. Once the
final administrative order has been issued, sunscreen manu-
facturers will have at least 1 year to ensure that products of-
fered on the shelves in the US are in compliance. The CARES
Act also incentivizes innovation by providing an opportunity
for an 18-month exclusivity period to the requesting manu-
facturer of a new filter. This exclusivity period begins on the
date when the manufacturer can lawfully market the sun-
screen ingredient. Notably, none of these provisions change
the safety testing that the FDA is requiring for category III sun-
screen ingredients listed in the 1999 proposed rule.1,2
The study by Tribby and colleagues3 confirms what most
clinicians have suspected from interacting with patients—
that the general public may not have enough information on
the key factors that should influence decision-making regard-
ing sunscreen selection. While most consumers look for SPF
values, and some might look for broad-spectrum labeling,
this study points to an opportunity for dermatologists to edu-
cate patients on the key factors to consider when choosing a
sunscreen.
Dermatologists are in the best position to educate the pub-
lic on the importance of photoprotection for skin health, in-
cluding seeking shade when outdoors; wearing photoprotec-
tive clothing, a wide-brimmed hat, and sunglasses; and
applying broad-spectrum sunscreen with an SPF 30 or higher.
Given the evolving information on sunscreen safety, the en-
vironmental consequences of sunscreen, and new sunscreen
regulations, dermatologists are in a unique position to edu-
cate the public on the proper practice of photoprotection and
to provide objective and updated information on sunscreens.
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